Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey
Miguel Lozano
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorNancy Heddle
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorLorna M Williamson
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorGrace Wang
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorJames P. AuBuchon
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorLarry J. Dumont
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorfor the Biomedical Excellence for Safer Transfusion (BEST) Collaborative
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorMiguel Lozano
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorNancy Heddle
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorLorna M Williamson
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorGrace Wang
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorJames P. AuBuchon
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorLarry J. Dumont
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorfor the Biomedical Excellence for Safer Transfusion (BEST) Collaborative
From the Hospital Clinic, Department of Hemotherapy and Hemostasis, IDIBAPS, Barcelona, Spain; the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the Department of Transfusion Medicine, National Blood Service, Cambridge, UK; Puget Sound Blood Center, Seattle, Washington; and the Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Search for more papers by this authorAbstract
BACKGROUND: There is a lack of evidence for guiding the best strategy for ABO selection of platelet (PLT) transfusions. As a baseline for future studies, the BEST Collaborative performed an international survey of current practices in this area.
STUDY DESIGN AND METHODS: An international survey was sent via BEST members to transfusion services and hospitals requesting the demographics of the transfused patient population, ABO matching policies, anti-A and anti-B measurements in PLT concentrates (PCs), and practices regarding ABO-incompatible PC transfusions to adult and pediatric patients.
RESULTS: We received 126 responses from 14 countries, 59% from Europe. Most of them were from local/community (42%) and university hospitals (39%) serving between 500 and 1500 beds; 50.4% transfused fewer than 1000 PCs per year. One-fifth of respondents (19.4%, mainly local/community hospitals) did not have a written policy for selecting ABO-incompatible PCs. Significant practice variation was reported when ABO-mismatched PLTs were given to adults: for PCs suspended in 100% plasma, 29% to 43% of respondents selected any ABO group available; 52% to 61% selected units with compatible supernatant; and, in the case of minor ABO incompatibility, 43% to 54% did not take any specific action. In contrast if ABO-identical PCs were not available for a pediatric recipient, for PCs resuspended in 100% plasma, 71% to 82% selected PCs so the supernatant plasma would be compatible with patient's red blood cells.
CONCLUSION: Considerable practice variation exists when transfusing ABO-incompatible PCs, suggesting an opportunity for research to inform evidence-based practices.
REFERENCES
- 1 Klein E, Djerassi I, Farber S. Maintenance of normal platelet levels in recipients of multiple transfusions of platelets from incompatible blood. Proceedings of the VIIth Congress of the International Society of Hematology. Rome, Sept. 7-13. 957, 1958.
- 2 Djerassi I, Farber S, Evans AE. Transfusion of fresh platelet concentrates to patients with secondary thrombocytopenia. N Engl J Med 1963; 268: 221-6.
- 3 Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABH antigens on human platelets. Blood 1985; 65: 615-9.
- 4 Tsuji T, Osawa T. Structures of the carbohydrate chains of membrane glycoproteins IIb and IIIa of human platelets. J Biochem 1986; 100: 1387-98.
- 5 Santoso S, Kiefel V, Mueller-Eckhardt C. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost 1991; 65: 196-201.
- 6 Skogen B, Rossebo HB, Husebekk A, Havnes T, Hannestad K. Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion 1988; 28: 456-9.
- 7 Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. Blood 1993; 82: 993-9.
- 8 Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000; 96: 1574-81.
- 9 Dunstan RA, Simpson MB. Heterogeneous distribution of antigens on human platelets demonstrated by fluorescence flow cytometry. Br J Haematol 1985; 61: 603-9.
- 10 Cooling LL, Kelly K, Barton J, Hwang D, Koerner TA, Olson JD. Determinants of ABH expression on human blood platelets. Blood 2005; 105: 3356-64.
- 11 Julmy F, Achermann F, Schulzki T, Carrel T, Nydegger U. PLTs of blood group A1 donors express increased surface A antigen owing to apheresis and prolonged storage. Transfusion 2003; 43: 1378-85.
- 12 Thon JN, Devine DV. Translation of glycoprotein IIIa in stored blood platelets. Transfusion 2007; 47: 2260-70.
- 13 Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26: 732-43.
- 14 Duguesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979; 54: 595-9.
- 15 Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23-30.
- 16 Klumpp TR, Herman JH, Innis S, Pearlman E, Culling N, Kotz KW, Slachta C, Goldberg SL, Mangan KF. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 17: 1035-41.
- 17 Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009; 49: 21-33.
- 18 Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993; 66: 309-14.
- 19 Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75: 408-13.
- 20 Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993; 85: 566-72.
- 21 Heal JM, Kenmotsu N, Rowe JM, Blumberg N. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994; 45: 189-90.
- 22 Benjamin RJ, Antin JH. ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion 1999; 39: 1273-4.
- 23 Blumberg N, Heal JM, Hicks GL, Risher WH. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 2001; 41: 790-3.
- 24 Lapierre V, Mahe C, Auperin A, Stambouli F, Oubouzar N, Tramalloni D, Benhamou E, Tiberghien P, Hartmann O. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005; 80: 314-9.
- 25 Shanwell A, Andersson TM, Rostgaard K, Edgren G, Hjalgrim H, Norda R, Melbye M, Nyrén O, Reilly M. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang 2009; 96: 316-23.
- 26 Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17: 57-68.
- 27 Fung MK, Downes KA, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med 2007; 131: 909-16.
- 28 British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
- 29 JB Gorlin, editor. Standards for blood banks and transfusion services. 21st ed. Bethesda (MD): American Association of Blood Banks; 2002.
- 30 Maclennan S. International Forum. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005; 88: 218-9.
- 31 Serious Hazards of Transfusion Steering Committee. Serious hazards of transfusion: annual report 2008. Manchester (UK): SHOT Office; 2009 [cited 2010 Mar 12]. Available from: URL: http://www.shotuk.org/SHOT%20Report%202008.pdf
- 32 Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007; 23: 20-33.
- 33 Valbonesi M, De Luigi MC, Lercari G, Bruni R, Van Lint MT, Occhini D. Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor. Int J Artif Organs 2000; 23: 642-6.
Citing Literature
